RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576

RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Vertex Pharmaceuticals (NASDAQ: VRTX) and increased the price target from $570 to $576. This adjustment reflects a positive outlook for the company's performance in the market.